sotagliflozin + norgestimate + ethinyl estradiol

This is a combination drug containing **sotagliflozin**, a dual sodium-glucose co-transporter 1 and 2 (SGLT1/2) inhibitor used primarily for diabetes management, and **norgestimate + ethinyl estradiol**, which is a well-established oral contraceptive combination used for birth control and treating acne in women. - **Sotagliflozin** lowers blood glucose by inhibiting SGLT1 in the gut and SGLT2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. - **Norgestimate** is a progestin and **ethinyl estradiol** is an estrogen; together, they suppress ovulation, alter cervical mucus and endometrial lining, preventing pregnancy[1][2][3].